Payment overview · 2025
General Payments
$573.83
26 reported records · 12 companies
Healthcare provider profile · identity verified
Mohammed Atiq Dada, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BAY CITY, TX · NPI 1942287826
Verified facts
What the public records show
CMS Open Payments records show Mohammed Atiq Dada, MD received $573.83 in general payments during 2025 across 26 reported records.
Amgen Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $113.32 | 19.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.50 | 17.7% | 5 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $99.29 | 17.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.56 | 12.1% | 4 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $33.16 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.15 | 5.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.12 | 4.4% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.11 | 4.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.82 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.51 | 3.6% | 1 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $17.61 | 3.1% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $15.68 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $573.83 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $99.29 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.75 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $69.56 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.56 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $65.56 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $47.76 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Allopurinol | Allopurinol | 548 | 161 |
| Furosemide | Furosemide | 514 | 177 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 280 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 62 |
| Carvedilol | Carvedilol | 195 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 62 |
| Ozempic | Semaglutide | 173 | 43 |
| Spironolactone | Spironolactone | 149 | 54 |
| Gabapentin | Gabapentin | 148 | 65 |
| Losartan Potassium | Losartan Potassium | 147 | 56 |
| Ezetimibe | Ezetimibe | 140 | 44 |
| Sertraline Hcl | Sertraline Hcl | 137 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 51 |
| Lisinopril | Lisinopril | 121 | 42 |
| Metformin Hcl | Metformin Hcl | 118 | 39 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 108 | 38 |
| Januvia | Sitagliptin Phosphate | 105 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 101 | 33 |
| Farxiga | Dapagliflozin Propanediol | 91 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 24 |
| Potassium Chloride | Potassium Chloride | 64 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 19 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Jardiance | Empagliflozin | 54 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 22 |
| Simvastatin | Simvastatin | 53 | 15 |
| Azithromycin | Azithromycin | 47 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 14 |
| Omeprazole | Omeprazole | 42 | 16 |
| Prednisone | Prednisone | 42 | 32 |
| Tradjenta | Linagliptin | 42 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 28 |
| Nifedipine Er | Nifedipine | 39 | 13 |
| Glipizide | Glipizide | 38 | 14 |
| Finasteride | Finasteride | 33 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 30 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 13 |
| Calcium Acetate | Calcium Acetate | 28 | 13 |
| Fluconazole | Fluconazole | 28 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 13 |
| Eliquis | Apixaban | 26 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | 12 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Colchicine | Colchicine | 15 | 13 |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $573.83 · 26 records | Amgen Inc. | FARXIGA, FUROSCIX, JYNARQUE, Korlym, OTEZLA, REPATHA, TARPEYO, TAVNEOS, TMS NeuroHealth Centers Inc., The Cologuard Plus Collection Kit, VRAYLAR, Vafseo, Xeomin, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error